Trial intelligence / Profile preview

Dasatinib with intensified chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

2010-022946-25Phase 3

Sponsor
Children's Oncology Group
Start
Dec 2011
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, open-label, single-arm trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by Children's Oncology Group. Primary endpoints: Feasibility, Toxicity and 2 more.

02

Drugs

dasatinib
03

Conditions

acute lymphoblastic leukemia (ALL)

Beyond the preview

Go deeper on 2010-022946-25.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-022946-25.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call